AUTHORS
Akira Yamamoto, MD, PhD., Yuichi Sumii, MD, PhD.2, Lihong Xu, N/A3, Lu Li, PhD4, Stephanie Kim, MD, PhD5, Tyler Leach, N/A6, Laure Maneix, PhD7, Meng-Chih Wu, N/A8, Yui Yamamoto, MD, PhD.9, Neelam Prakash Bodhale, PhD10, Takashi Ikeda, MD, PhD.11, Victoria Ontiveros, N/A12, Ana Santibanez, N/A13, Dongchang Zhao, MD, PhD.14, Yaping Sun, MD, PhD.15, Pavan Reddy, MD16
AFFILIATIONS
1 Baylor College of Medicine, Houston, Texas, United States
2 Baylor College of Medicine, Houston, Texas, United States
3 Baylor College of Medicine, Houston, Texas, United States
4 Baylor College of Medicine, Houston, Texas, United States
5 Baylor College of Medicine, Houston, Texas, United States
6 Baylor College of Medicine, Houston, Texas, United States
7 Baylor College of Medicine, Houston, Texas, United States
8 Baylor College of Medicine, Houston, Texas, United States
9 Baylor College of Medicine, Houston, Texas, United States
10 Baylor College of Medicine, Houston, Texas, United States
11 Baylor College of Medicine, Houston, Texas, United States
12 Baylor College of Medicine, Houston, Texas, United States
13 Baylor College of Medicine, Houston, Texas, United States
14 Baylor College of Medicine, Houston, Texas, United States
15 Baylor College of Medicine, Houston, Texas, United States
16 Baylor College of Medicine, Houston, Texas, United States
ABSTRACT
Activated T cells must coordinate proliferation, cytokine secretion, lipid biosynthesis, and cytotoxicity. The trafficking mechanisms that integrate these distinct programs remain unknown. Here we discover SEC23B-dependent COPII trafficking as a checkpoint that links ER-to-Golgi trafficking to SREBP-1-dependent metabolic programming that dissociates T-cell proliferation and inflammatory cytokine secretion from cytotoxic immunity.
Splenic and lymph node-derived T cells from Sec23bfl/fl CD4-Cre+ (KO) B6 mice and littermate Sec23bfl/fl CD4-Cre- wild type (WT) B6 controls showed no phenotypic or quantitative differences at baseline. Cells were stimulated with anti-CD3/CD28 antibodies or allogeneic (BALB/c) dendritic cells and assessed for T-cell activation, proliferation, cytokine secretion, cytotoxicity, single-cell transcriptomics, metabolic function, SREBP-1 processing, and lipid biosynthesis, as well as for antitumor immunity and graft-versus-host disease (GVHD) in vivo following a C57BL/6(H-2b) → BALB/c(H-2d) MHC-mismatched bone marrow transplantation. Three orthogonal strategies were utilized to demonstrate causal mechanisms: SEC23A genetic complementation, cholesterol supplementation, and rescue by constitutively active nuclear SREBP-1.
SEC23B deficiency preserved proximal T-cell receptor signaling, including ZAP70 and ERK phosphorylation, but markedly reduced proliferation (P < 0.0001) and secretion of IL-2, IFN-γ, and TNF-α. In contrast, SEC23B-deficient CD8 T cells displayed enhanced cytotoxicity against allogeneic tumor targets (P < 0.0001), increased intracellular perforin (P < 0.0001), and preserved granzyme-mediated effector function. In vivo, SEC23B deficiency improved control of syngeneic tumors (P < 0.05), markedly reduced GVHD (P < 0.0001 at day 21), and preserved graft-versus-tumor activity across multiple donor T-cell doses against P815 and A20 tumors. Thus, at matched T-cell doses, SEC23B loss disassociated allo-inflammatory expansion from cytotoxic immunity.
Single-cell RNA sequencing revealed altered cell-cycle progression, with increased representation of SEC23B-deficient cells in S phase and reduced representation in G2/M (both P < 0.05). Hallmark pathway analysis demonstrated that cholesterol homeostasis (NES = 2.58; FDR q = 6.3 × 10⁻¹⁰) and fatty acid metabolism (NES = 1.61; FDR q = 9.9 × 10⁻³) were coordinately suppressed in KO T cells. SREBP-1 target genes involved in fatty acid and cholesterol biosynthesis were significantly reduced. We next tested whether these defects resulted from impaired COPII-dependent ER-to-Golgi processing of SREBP-1 before its nuclear translocation. Activated WT T cells showed perinuclear colocalization of SEC23B and SREBP-1, whereas SEC23B-deficient T cells accumulated precursor SREBP-1 but exhibited reduced mature nuclear SREBP-1 (P < 0.01) and reduced intracellular lipid accumulation (P < 0.05). These findings identified defective SREBP-1 activation as the principal metabolic consequence of impaired COPII trafficking.
We then interrogated this SEC23B-Cholesterol-SREBP-1 axis at three successive levels with distinct rescue approaches. Because increased expression of the paralog SEC23A is known to compensate for SEC23B deficiency, we next analyzed B6-Sec23b-a/b-a mice, which lack Sec23b but express Sec23a from the endogenous Sec23b genomic locus, thereby restoring total SEC23 protein to WT levels. SEC23A complementation of KO T cells restored nuclear SREBP-1 maturation, lipid biosynthesis, proliferation, cytokine secretion, and normalized the enhanced cytotoxic phenotype. Cholesterol supplementation partially rescued proliferation. Constitutive expression of active nuclear SREBP-1 in KO T cells restored proliferation to WT levels, demonstrating that defective SREBP-1 activation is the critical downstream consequence of SEC23B deficiency and completing the mechanistic link between COPII trafficking, metabolic programming, and T-cell function.
Our findings uncover SEC23B-dependent COPII transport of SREBP-1 as a previously unrecognized metabolic checkpoint that dictates whether an activated T cell allocates resources toward expansion or cytotoxic killing. By coupling intracellular trafficking to SREBP-1 activation and lipid biosynthesis, COPII trafficking represents a potential selective therapeutic target for limiting pathogenic alloimmunity while preserving antitumor immunity.
DISCLOSURES
Akira Yamamoto, MD, PhD.: No relevant conflicts of interest to declare.